Share Prices & Company Research

Stockbroking

Indivior

Current Price 40.10p Bid 40.10p Ask 40.14p Change -5.11%
Last Updated: 16/12/2019 00:31. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Indivior plc is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline Focus on you makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide.

Financial Highlights Year Ended 31/12/2018

Turnover
£1,005.00m
Operating Profit
£292.00m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
1.06

Key Personnel

Shaun Thaxter
Chief Executive Officer
Mark Wesley Crossley
Chief Financial Officer
Howard Hao Pien
Executive Chairman
Dr Andrew Thomas McLellan
Non-Executive Director
Peter James Jonathan Bains
Non-Executive Director
Tatjana Anni Hilde May
Non-Executive Director
Daniel Tasse
Non-Executive Director
Daniel Joseph Phelan
Non-Executive Director
Lorna Mary Southcombe Parker
Non-Executive Director
Graham Charles Hetherington
Non-Executive Director

Stock Details

EPIC
INDV
ISIN
GB00BRS65X63
Shares in Issue
730,765,489
Market cap
£294.79m

Analyst Views (2)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
100.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
40.10p
Bid Price
40.10p
Ask Price
40.14p
Volume
2234553
Change Today
-2.16p
% Change Today
-5.11%
Open
42.80p
Previous Close
40.10p
Intraday High
42.80p
Intraday Low
39.80p
52 Week High
130.55p
52 Week Low
20.98p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Indivior Intra-day Chart

Indivior News

News in this section is provided by AJ Bell

UK stocks recover losses on Brexit deal hopes, sterling gains 15 Oct 2019 | 16:47 UK stocks drift lower ahead of key US banking results 15 Oct 2019 | 13:02 FTSE opens up 0.1% as investors eye crucial Brexit, US-China trade talks 15 Oct 2019 | 08:53 Indivior upgrades profit outlook on stronger sales of opioid addiction drug 15 Oct 2019 | 08:02 Director Deals - Indivior Plc (INDV) 13 Aug 2019 | 14:45 Director Deals - Indivior Plc (INDV) 09 Aug 2019 | 09:05 Indivior profits rises in Q2 as opioid addiction treatment fares better than expected 31 Jul 2019 | 09:53 FTSE dips despite bright US start 11 Jul 2019 | 16:38 FTSE falls flat by midday, sterling enjoys gains 11 Jul 2019 | 12:06 Indivior raises guidance as opioid addiction treatment fares better than expected in H1 11 Jul 2019 | 08:26 Indivior opioid addiction treatment shown to have possible long-lasting effects 18 Jun 2019 | 13:32 Director Deals - Indivior Plc (INDV) 15 May 2019 | 09:00 Director Deals - Indivior Plc (INDV) 15 May 2019 | 09:00 Director Deals - Indivior Plc (INDV) 13 May 2019 | 16:35 FTSE retreats as sterling rises ahead of EU summit 10 Apr 2019 | 16:47 Reckitt Benckiser responds to US indictment of Indivior 10 Apr 2019 | 13:12 FTSE continues to flatline ahead of key EU summit 10 Apr 2019 | 12:01 FTSE posts modest gains as May contemplates long Brexit delay 10 Apr 2019 | 08:54 Indivior faces series of charges over fraudulent activity in US 10 Apr 2019 | 08:03 FTSE flat amid firmer pound, German export slump 08 Apr 2019 | 11:58 UK stocks open 0.2% lower as pound firms 08 Apr 2019 | 08:55 Indivior presents data to help tackle opioid abuse 08 Apr 2019 | 07:57 Indivior presents opioid addiction treatment study findings at Florida gathering 05 Apr 2019 | 13:45 Indivior launches injectable schizophrenia treatment in US 27 Feb 2019 | 13:18 FTSE remains in positive territory despite Sainsbury's slide 20 Feb 2019 | 12:09 Indivior launches generic opioid addiction treatment to stave off competition from rivals 20 Feb 2019 | 08:04 Indivior's opioid addiction treatment meets primary, secondary goals 19 Feb 2019 | 09:19 Broker Forecast - Jefferies International issues a broker note on Indivior Plc 18 Feb 2019 | 10:20 Indivior cost cuts help boost profits; warns of 'imminent' risk from copycat products 14 Feb 2019 | 09:09 FTSE fails to follow Wall Street higher 12 Feb 2019 | 16:48

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
57.0
54.0
Intangible Assets & Goodwill
84.0
92.0
Investments & Other Non-Current Assets
77.0
73.0
Total Non-Current Assets
218.0
219.0
Inventory
78.0
52.0
Trade & Receivables
287.0
278.0
Cash & Receivables
924.0
863.0
Other Current Assets & Assets Held for Resale
40.0
32.0
Total Assets
1,547.0
1,444.0

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
818.0
854.0
Long Term Liabilities
663.0
793.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
1,481.0
1,647.0

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
66.0
-203.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
73.0
72.0
Minority Interests
0.0
0.0
Retained Earnings
1,315.0
1,032.0
Share Premium Account
5.0
2.0
Other Equity
-1,327.0
-1,309.0
Total Equity
66.0
-203.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
303.0
295.0
Cashflow Before Financing
307.0
252.0
Increase / Decrease in Cash
62.0
168.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
1,005.0
1,093.0
Cost of Sales
128.0
104.0
Gross Profit
877.0
989.0
Operating Profit
292.0
193.0
Pre-Tax Profit
278.0
137.0
Profit / Loss for the Year
275.0
58.0

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H2 Dividend
16 Jun 2016
29 Jul 2016
H1 Dividend
17 Sep 2015
23 Oct 2015
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.